The Growth Potential Of Psychedelics Stocks And ETFs

Jul. 28, 2022 1:54 PM ETATAI, CMPS, CYBN, MNMD, PSIL, PSY, PSYK, SEEL, RVVTF8 Comments
Marcia Wendorf profile picture
Marcia Wendorf


  • On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members.
  • A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.
  • Across the U.S., veterans groups are demanding access to psychedelics to help treat their PTSD.
  • Cities around the country are deprioritizing or decriminalizing psychedelics.
  • On Jan. 1, 2023, Oregon will become the first state to allow psychotherapists to treat their patients using psilocybin.

Psychedelics Business

wildpixel/iStock via Getty Images

A Psychedelic Resurgence

In 2018, writer Michael Pollan published How to Change Your Mind, an in-depth look at the resurgence of psychedelics in the treatment of mental illnesses. Recently, Netflix (NFLX) released a video

ATAI Life Sciences 1-year price chart

Atai Life Sciences 1-year price chart (Seeking Alpha)

Compass Pathways 1-year price chart

COMPASS Pathways 1-year price chart (Seeking Alpha)

Cybin Inc. 1-year price chart

Cybin Inc. 1-year price chart (Seeking Alpha)

MindMed Medicine 1-year price chart

Mind Medicine 1-year price chart (Seeking Alpha)

Seelos Therapeutics 1-year price chart

Seelos Therapeutics 1-year price chart (Seeking Alpha)

This article was written by

Marcia Wendorf profile picture
Marcia is a former high school math teacher, technical writer, author, and programmer. She stays on top of worldwide news about science, government policies, finance, infrastructure, and medical issues. She is always "sniffing the wind" for the latest trends and directions, and keeping her readers abreast of these developments.

Disclosure: I/we have a beneficial long position in the shares of CMPS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.